Immunome, Inc. (NASDAQ:IMNM) Receives $29.00 Average Target Price from Analysts

Immunome, Inc. (NASDAQ:IMNM) has been assigned an average recommendation of “Buy” from the six brokerages that are covering the firm, Marketbeat reports. Six analysts have rated the stock with a buy rating. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $29.00.

IMNM has been the subject of several research analyst reports. Piper Sandler decreased their price objective on Immunome from $27.00 to $23.00 and set an “overweight” rating for the company in a report on Tuesday, August 13th. Wedbush reiterated an “outperform” rating and set a $33.00 price target on shares of Immunome in a research note on Friday, October 25th.

Insider Transactions at Immunome

In related news, Director Jean Jacques Bienaime purchased 7,000 shares of the stock in a transaction that occurred on Friday, August 16th. The stock was purchased at an average cost of $13.94 per share, for a total transaction of $97,580.00. Following the acquisition, the director now owns 16,615 shares in the company, valued at approximately $231,613.10. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Jean Jacques Bienaime purchased 7,000 shares of the stock in a transaction that occurred on Friday, August 16th. The stock was acquired at an average cost of $13.94 per share, with a total value of $97,580.00. Following the acquisition, the director now owns 16,615 shares in the company, valued at approximately $231,613.10. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Max Rosett sold 14,380 shares of the business’s stock in a transaction on Thursday, September 19th. The stock was sold at an average price of $16.01, for a total transaction of $230,223.80. Following the completion of the transaction, the chief financial officer now owns 47,476 shares in the company, valued at $760,090.76. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 8.60% of the company’s stock.

Institutional Trading of Immunome

Institutional investors have recently added to or reduced their stakes in the business. Quest Partners LLC bought a new position in Immunome during the 2nd quarter worth $81,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Immunome during the second quarter valued at about $97,000. Arizona State Retirement System grew its position in Immunome by 9.2% in the 2nd quarter. Arizona State Retirement System now owns 10,862 shares of the company’s stock valued at $131,000 after buying an additional 918 shares in the last quarter. EntryPoint Capital LLC increased its stake in Immunome by 21,864.0% during the 1st quarter. EntryPoint Capital LLC now owns 5,491 shares of the company’s stock valued at $136,000 after buying an additional 5,466 shares during the period. Finally, AQR Capital Management LLC increased its stake in shares of Immunome by 34.6% during the second quarter. AQR Capital Management LLC now owns 16,064 shares of the company’s stock valued at $194,000 after acquiring an additional 4,129 shares during the period. Institutional investors own 44.58% of the company’s stock.

Immunome Trading Up 1.0 %

Shares of IMNM opened at $11.59 on Friday. The firm has a market capitalization of $695.98 million, a price-to-earnings ratio of -1.51 and a beta of 1.82. The firm’s fifty day simple moving average is $13.63 and its 200-day simple moving average is $13.99. Immunome has a twelve month low of $6.93 and a twelve month high of $30.96.

Immunome (NASDAQ:IMNM) last issued its earnings results on Monday, August 12th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.11). The business had revenue of $2.36 million for the quarter, compared to analyst estimates of $2.62 million. Immunome had a negative return on equity of 38.19% and a negative net margin of 2,435.02%. On average, analysts predict that Immunome will post -1.92 earnings per share for the current fiscal year.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.